What is SKNV?
Founded in 2015, SKNV operates as a critical player in the pharmaceutical supply chain by producing customized dermatological medications. The company's 503B outsourcing facility model is designed to bypass traditional intermediaries, thereby ensuring that patients receive essential treatments with greater affordability and promptness. SKNV adheres strictly to Current Good Manufacturing Practices (CGMP) and collaborates directly with healthcare providers to offer a diverse portfolio of over 120 unique formulations, significantly enhancing patient care within the dermatology sector.
How much funding has SKNV raised?
SKNV has raised a total of $35M across 1 funding round:
Private Equity
$35M
Private Equity (2022): $35M with participation from Accelmed Partners
Key Investors in SKNV
Accelmed Partners
Accelmed Partners is a private equity firm that likely focuses on investments within the healthcare and medical technology sectors, potentially specializing in companies that offer innovative solutions to the pharmaceutical and healthcare industries.
What's next for SKNV?
With its recent major strategic investment and substantial total funding, SKNV is poised for accelerated growth and enhanced operational capabilities. The company's focus on direct collaboration with healthcare providers and its commitment to CGMP standards position it favorably for scaling its customized medication production. This capital infusion is anticipated to bolster SKNV's efforts in further optimizing the pharmaceutical supply chain, expanding its formulation offerings, and solidifying its role as a key provider of specialized dermatological treatments.
See full SKNV company page
